佰金生命科學(01466.HK)擬發行6535.94萬股認購股份 總籌3137.3萬港元
格隆匯3月18日丨佰金生命科學(01466.HK)發佈公告,2025年3月18日,公司(作爲發行人)與認購人各自訂立單獨認購協議,以按認購價每股股份0.48港元認購合共6535.94萬股認購股份。認購價爲每股認購股份0.48港元,較3月18日(即認購協議日期)在聯交所所報收市價每股0.5港元折讓約4.00%。
根據認購協議將予配發及發行的認購股份相當於本公告日期現有已發行股本約9.24%;以及經配發及發行認購股份擴大後已發行股本約8.46%。認購股份將根據一般授權配發及發行。公司將向聯交所申請批準認購股份上市及買賣。認購事項的所得款項總額將約爲3137.3萬港元。認購事項的所得款項淨額估計約爲3127.3萬港元。公司擬將認購事項的所得款項淨額用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.